Coexistence of Graves’ disease and unilateral functioning Struma ovarii: a case report

BMC Endocrine Disorders

Nuntakorn Thongtang¹  Thavatchai Peerapatdit¹  Suchanan Hanamornroongruang²  Tullaya Sitasuwan¹ 

[1] Division of Endocrinology and Metabolism, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand;Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

关键词: Functioning struma ovarii;    Graves’ disease;   

Others  :  1230282
DOI  :  10.1186/s12902-015-0060-z

 received in 2015-08-31, accepted in 2015-10-20,  发布年份 2015

【 摘 要 】

Background

Coexisting of Graves’ disease and functioning struma ovarii is a rare condition. Although the histology of struma ovarii predominantly composed of thyrocytes, the majority of the patients did not have thyrotoxicosis. The mechanism underlying the functioning status of the tumor is still unclear but the presence of thyroid stimulating hormone receptor (TSHR) is thought to play a role. Here we describe the patient presentation and report the TSHR expression of the tumor.

Case presentation

A 56-year old Asian woman presented with long standing thyrotoxicosis for 23 years. She was diagnosed with Graves’ disease and thyroid nodules. She had bilateral exophthalmos and had high titer of plasma TSHR antibody. Total thyroidectomy was performed and the histologic findings confirmed the clinical diagnosis. The patient had persistent thyrotoxicosis postoperatively. Thyroid uptake demonstrated the adequacy of the thyroid surgery and the whole body scan confirmed the presence of functioning thyroid tissue at pelvic area. The surgery was scheduled and the patient had hypothyroidism after the surgery. The pathological diagnosis was struma ovarii at right ovary. We performed TSHR staining in both the patient’s struma ovarii and in 3 cases of non-functioning struma ovarii. The staining results were all positive and the intensity of the TSHR staining of functioning struma ovarii was the same as that in other cases of non-functioning tumors, suggesting that the determinant of functioning struma ovarii might be the presence of TSHR stimuli rather than the intensity of the TSHR in the ovarian tissue.

Conclusion

In patients with Graves’ disease with persistent or recurrent thyrotoxicosis after adequate ablative treatment, the possibility of ectopic thyroid hormone production should be considered. TSHR expression is found in patients with functioning and non-functioning struma ovarii and cannot solely be used to determine the functioning status of the tumor.

【 授权许可】

   
2015 Sitasuwan et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Bayot MR, Chopra IJ. Coexistence of struma ovarii and Graves’ disease. Thyroid. 1995; 5(6):469-71.
• [2]Wong LY, Diamond TH. Severe ophthalmopathy developing after treatment of coexisting malignant struma ovarii and Graves’ disease. Thyroid. 2009; 19(10):1125-7.
• [3]Anastasilakis AD, Ruggeri RM, Polyzos SA, Makras P, Molyva D, Campenni A et al.. Coexistence of Graves’ disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature. Metabolism. 2013; 62(10):1350-6.
• [4]Teale E, Gouldesbrough DR, Peacey SR. Graves’ disease and coexisting struma ovarii: struma expression of thyrotropin receptors and the presence of thyrotropin receptor stimulating antibodies. Thyroid. 2006; 16(8):791-3.
• [5]Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol. 1993; 12(4):333-43.
• [6]Mimura Y, Kishida M, Masuyama H, Suwaki N, Kodama J, Otsuka F et al.. Coexistence of Graves’ disease and struma ovarii: case report and literature review. Endocr J. 2001; 48(2):255-60.
• [7]Kempers RD, Dockerty MB, Hoffman DL, Bartholomew LG. Struma ovarii--ascitic, hyperthyroid, and asymptomatic syndromes. Ann Intern Med. 1970; 72(6):883-93.
• [8]Kano H, Inoue M, Nishino T, Yoshimoto Y, Arima R. Malignant struma ovarii with Graves’ disease. Gynecol Oncol. 2000; 79(3):508-10.
• [9]Lefort G, Commenges-Ducos M, Denechaud M, Rivel J, Latapie JL. Ovarian goiter in Basedow’s disease. Role of thyroid-stimulating immunoglobulins? Nouv Presse Med. 1981; 10(26):2209-10.
• [10]Kung AW, Ma JT, Wang C, Young RT. Hyperthyroidism during pregnancy due to coexistence of struma ovarii and Graves’ disease. Postgrad Med J. 1990; 66(772):132-3.
• [11]Guida M, Mandato VD, Di Spiezio SA, Di Carlo C, Giordano E, Nappi C. Coexistence of Graves’ disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. J Endocrinol Invest. 2005; 28(9):827-30.
• [12]Ghander C, Lussato D, Conte Devolx B, Mundler O, Taieb D. Incidental diagnosis of struma ovarii after thyroidectomy for thyroid cancer: functional imaging studies and follow-up. Gynecol Oncol. 2006; 102(2):378-80.
• [13]Joja I, Asakawa T, Mitsumori A, Nakagawa T, Akaki S, Yamamoto M et al.. I-123 uptake in nonfunctional struma ovarii. Clin Nucl Med. 1998; 23(1):10-2.
• [14]Nodine JH, Maldia G. Pseudostruma ovarii. Obstet Gynecol. 1961; 17:460-3.
• [15]Lazarus JH, Richards AR, MacPherson MJ, Dinnen JS, Williams ED, Owen GM et al.. Struma ovarii: a case report. Clin Endocrinol (Oxf). 1987; 27(6):715-20.
• [16]Grandet PJ, Remi MH. Struma ovarii with hyperthyroidism. Clin Nucl Med. 2000; 25(10):763-5.
• [17]Sussman SK, Kho SA, Cersosimo E, Heimann A. Coexistence of malignant struma ovarii and Graves’ disease. Endocr Pract. 2002; 8(5):378-80.
• [18]Bartel TB, Juweid ME, O’Dorisio T, Sivitz W, Kirby P. Scintigraphic detection of benign struma ovarii in a hyperthyroid patient. J Clin Endocrinol Metab. 2005; 90(6):3771-2.
• [19]Chiofalo MG, Misso C, Insabato L, Lastoria S, Pezzullo L. Hyperthyroidism due to coexistence of Graves’ disease and Struma ovarii. Endocr Pract. 2007; 13(3):274-6.